Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2058-7716
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia ; volume:8 ; number:1 ; day:1 ; month:7 ; year:2022 ; pages:1-11 ; date:12.2022
Cell death discovery ; 8, Heft 1 (1.7.2022), 1-11, 12.2022

Creator
Richter, Anna
Lange, Sandra
Holz, Clemens
Brock, Luisa
Freitag, Thomas
Sekora, Anett
Knuebel, Gudrun
Krohn, Saskia
Schwarz, Rico
Hinz, Burkhard
Murua Escobar, Hugo
Junghanss, Christian
Contributor
SpringerLink (Online service)

DOI
10.1038/s41420-022-01093-3
URN
urn:nbn:de:101:1-2022082119044437194077
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:34 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Richter, Anna
  • Lange, Sandra
  • Holz, Clemens
  • Brock, Luisa
  • Freitag, Thomas
  • Sekora, Anett
  • Knuebel, Gudrun
  • Krohn, Saskia
  • Schwarz, Rico
  • Hinz, Burkhard
  • Murua Escobar, Hugo
  • Junghanss, Christian
  • SpringerLink (Online service)

Other Objects (12)

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia

NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia

Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes

Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes

Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia

Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia

Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia

Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia

Efficacy and molecular mechanisms of the BH3-mimetic venetoclax (ABT-199) in pediatric acute lymphoblastic leukemia

Efficacy and molecular mechanisms of the BH3-mimetic venetoclax (ABT-199) in pediatric acute lymphoblastic leukemia

Acute lymphoblastic leukemia

Acute lymphoblastic leukemia

RNA binding proteins in MLL-rearranged leukemia

RNA binding proteins in MLL-rearranged leukemia

T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”

T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”

Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax

Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax

Relapsed Acute Lymphoblastic Leukemia

Relapsed Acute Lymphoblastic Leukemia

Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia

Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia

Related objects